Multidisciplinary Head and Neck Cancers Symposium 2022

Multidisciplinary Head and Neck Cancers Symposium 2022

€20,00
/
Tax included. Shipping calculated at checkout.
  • Free Shipping on orders over 45$
  • In stock, ready to ship
  • Inventory on the way
Multidisciplinary Head and Neck Cancers Symposium 2022 The 2022 Multidisciplinary Head and Neck Cancers Symposium will take place February 24-26, 2022, in Phoenix, Arizona. This practical and interactive meeting is for the entire head and neck cancer care community. The program will provide the most up-to-date information on multidisciplinary therapies, the latest clinical research, new treatment strategies, supportive care, scientific breakthroughs and toxicity mitigation.

  • When:  Feb 24, 2022

Presented by American Head & Neck Society, American Society of Clinical Oncology, American Society for Radiation Oncology and the Society for Immunotherapy of Cancer
+ Target Audience: medical oncologists, radiation oncologists, surgeons, physicists, nurses, diagnostic radiologists, pathologists, radiation therapists, radiation dosimetrists, speech language pathologists/scientists, dentists, oral surgeons, swallowing and speech therapists, audiologists, physical therapists, scientists, immunologist and rehabilitation specialists

 

 Topics:
  • Agenda.pdf
  • Thursday, February 24, 2022 Part 1.mp4
  • Thursday, February 24, 2022 Part 2.mp4
  • Friday, February 25, 2022 Part 1.mp4
  • Friday, February 25, 2022 Part 2.mp4
  • Saturday, February 26, 2022.mp4

 

* Detail:

Wednesday, February 23, 2022


4:00 p.m. – 6:00 p.m. Registration Open
Thursday, February 24, 2022

7:00 a.m. – 4:30 p.m. Registration Open
7:00 a.m. – 8:00 a.m. Continental Breakfast
7:50 a.m. – 8:00 a.m. Day One Welcome
Cherie-Ann Nathan, MD, Louisiana State University-Health, Shreveport, Louisiana [HNS]
8:00 a.m. – 8:20 a.m. Patient Perspective: Building a Community of HNL Patients, Coaches and Mentors
Speaker: Michael West
8:20 a.m. – 9:50 a.m. Patient-centric Head and Neck Care 
Moderator: Cherie-Ann Nathan, MD, Louisiana State University-Health, Shreveport, Louisiana [HNS]
  • Comprehensive Rehabilitation of the Head and Neck Patient
    • Heather Starmer, MA, CCC-SLP, BCS-S, Stanford University, Stanford, California [SLP]
  • Oral/Dental Needs in HNC Survivors
    • Joel Epstein, DMD, MSD, Cedars-Sinai, Los Angeles [OMFS]
  • Addressing the Psychological Aspects of Head and Neck Cancer
    • Elizabeth Cash, PhD, University of Louisville, Louisville, Kentucky [Psychologist]
  • The Artistry of Facial Prosthetics
    • Devin Okay, DDS, Mount Sinai Hospital, New York [OMFS]
  • Nutrition in Head and Neck Cancer
    • Patricia Rubio, MBA, MS, University of California, San Diego [Nutritionist]
  • Questions and Answers
9:50 a.m. – 10:35 a.m. Keynote I: Disparities in Head and Neck Cancer
Moderator: Dan Zandberg, MD, University of Pittsburgh Medical Center, Pittsburgh [M]
  • Sharon Spencer, MD, University of Alabama at Birmingham, Birmingham, Alabama [R]
  • Charles Moore, MD, Emory University, Atlanta [HNS]
10:35 a.m. – 11:00 a.m. Coffee Break
11:00 a.m. – 12:30 p.m. Escalation Strategies and Novel Approaches in Locally Advanced Head and Neck Cancer
Moderator: Julie Bauman, MD, MPH, University of Arizona, Tucson, Arizona [M]
  • Immunotherapy in the Curative Intent Setting
    • Sana Karam, MD, PhD, University of Colorado, Denver [R]
  • The Role of Preop IO in Locally Advanced HNC
    • Ravi Uppaluri, MD, PhD, Brigham and Women’s Hospital, Boston [HNS]
  • Novel Radiosensitizers
    • Heath Skinner, MD, PhD, University of Pittsburgh,  Pittsburgh [R]​
  • Nasopharynx: Induction vs Adjuvant – Where do we go from here?
    • Dimitrios Colevas, MD, Stanford University, Stanford, California [M]
  • Questions and Answers
12:30 p.m. – 1:30 p.m. Lunch in the Exhibit Hall
Early-career and Trainee Networking Luncheon: Choosing Your Career Path
Highlight careers briefly at the beginning and then break out into small groups at the different round tables.
Moderator: Maie St. John, MD, PhD, UCLA David Geffen, Los Angeles [HNS]
  • Julie Bauman, MD, MPH, University of Arizona, Tucson, Arizona [M]
  • Katherine Hutcheson, PhD, MD Anderson Cancer Center, Houston [Speech Path]
  • Faye Johnson, MD, PhD, MD Anderson Cancer Center, Houston [M]
  • Loren Mell, MD, University of California, San Diego [R]
  • Maie St. John, MD, PhD, UCLA David Geffen, Los Angeles [HNS]
1:30 p.m. – 3:00 p.m. K. Kian Ang, MD, PhD, FASTRO, Commemorative Plenary Session
Moderator: Maie St. John, MD, PhD, UCLA David Geffen, Los Angeles [HNS]
  • Early Toxicity and Patient Reported Outcomes from a Phase 2 Trial of FDG-PET Response-based De-escalated Definitive Radiotherapy for p16+ Oropharynx Cancer
    • Steven Allen, University of Michigan, Ann Arbor, Michigan
  • Non-inferiority Margin and Nodal Analysis of De-escalated Adjuvant Radiation Therapy (DART) for HPV-related Oropharyngeal Squamous Cell Carcinoma (OPSCC): A Preplanned Pooled Analysis of MC1273 & MC1675
    • Daniel Ma, Mayo Clinic, Rochester, Minnesota
  • Detection of Occult Recurrence Using Circulating HPV Tumor DNA among Patients Treated for HPV-driven Oropharyngeal Squamous Cell Carcinoma
    • Glenn Hanna, Dana-Farber Cancer Institute, Harvard Medical School, Boston
  • Kinetics of Circulating Human Papillomavirus (cHPV) DNA in Plasma and Oral Gargles from Patients with HPV-positive Oropharyngeal Cancer (OPC) Treated with Definitive Radiation Therapy
    • Michelle Echevarria, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
  • A Clinically Translatable, Extensively Validated Immune-based Classification of Human Papillomavirus-associated Head and Neck Cancer with Implications for Treatment Deintensification and Immunotherapy
    • Peter Zeng, Western University, London, Ontario, Canada
  • Predicted Th2 Infiltrate is Associated with Outcome in HPV(-) Head and Neck Cancer
    • Mohamed Abdelhakiem, UPMC Hillman Cancer Center, Pittsburgh
  • Loss of HPV 16- E2 Predicts Disease Free Survival and Promotes Platinum Resistance in Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma
    • Molly Heft-Neal, University of Michigan, Ann Arbor, Michigan
  • Neoadjuvant Immunoradiotherapy in a Tobacco-Signature Preclinical Oral Squamous Cell Carcinoma Model
    • Robert Saddawi-Konefka, University of California, San Diego
  • HPV E5 Mediates Resistance to PD-1 Checkpoint Blockade via Inhibition of MHC and IFN Pathway
    • Andrew Sharabi, University of California, San Diego
3:00 p.m. – 3:30 p.m. Coffee Break
3:30 p.m. – 4:30 p.m. Case Study and Debate: Curative Intent in Elderly and Frail
Moderator: Zain Husain, MD, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada [R]
  • Susan McCammon, MD, University of Alabama, Birmingham, Birmingham, Alabama [HNS]
  • Loren Mell, MD, University of California, San Diego [R]
  • Paul Loren Swiecicki, MD, University of Michigan, Ann Arbor, Michigan [M]
  • Questions and Answers
4:30 p.m. – 5:30 p.m. Research Feature and Networking Reception
Friday, February 25, 2022

7:00 a.m. – 5:30 p.m. Registration Open
7:00 a.m. – 8:00 a.m. Continental Breakfast
7:55 a.m. – 8:00 a.m. Day Two Welcome
Quynh-Thu Le, MD, FASTRO, Stanford University, Stanford, California [R]
8:00 a.m. – 8:20 a.m. Patient Perspective
Speaker: Andy Pluemer
8:20 a.m. – 9:40 a.m. HOT TOPIC: Early Oral Cavity
Moderator: Mike Moore, MD, Indiana University of Medicine, Indianapolis [HNS]
  • Tumor Board
  • Intraoperative Margin Assessment
    • Mark Varvares, MD, FACS, Massachusetts General Hospital, Boston [HNS]
  • Pathologist’s Perspective
    • Margaret Brandwein-Weber, MD, Mount Sinai, New York [Pathologist]
  • Sentinel Node and Neck Dissection
    • Stephen Lai, MD, PhD, FACS, MD Anderson Cancer Center, Houston [HNS]
  • New Frontiers in Sx: Fluorescence Guided Sx
    • Eben Rosenthal, MD, Vanderbilt University Medical Center, Nashville [HNS]
  • Surgical Reconstruction
    • Kelly Malloy, MD, University of Michigan, Ann Arbor, Michigan [HNS]
9:40 a.m. – 10:25 a.m. Keynote II: Towards Personalization of HPV Related Oropharyngeal Carcinoma
Moderator: Quynh-Thu Le, MD, FASTRO, Stanford University, Stanford, California [R]
Speaker: Nancy Lee, MD, FASTRO, Memorial Sloan Kettering Cancer Center, New York [R]
10:25 a.m. – 10:50 a.m. Coffee Break
10:50 a.m. – 12:20 p.m. Plenary II
Moderator: Alexander Pearson, MD, PhD, University of Chicago, Chicago [M]
  • An Artificial Intelligence Ultrasound Platform for Screening and Staging of Thyroid Cancer
    • Annie Chan, Massachusetts General Hospital, Harvard Medical School, Boston
  • Development of a Deep Learning-based Auto-segmentation of Organs at Risk for Head and Neck Radiotherapy Planning
    • Jihye Koo, University of South Florida, Tampa, Florida
  • Safety and Efficacy of RP1 + Nivolumab in Patients with Non-melanoma Skin Cancer of the Head and Neck: Results From IGNYTE Phase 1/2 Multi-cohort Clinical Trial
    • Jiaxin Niu, Banner MD Anderson Cancer Center, Houston
  • A Novel Intratumoral Microdosing Approach for Simultaneously Evaluating Multiple Drugs and Combinations in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC)
    • Harrison Cash, University of Washington Medical Center, Seattle
  • Efficacy and Safety of Tisotumab Vedotin in Patients with Head and Neck Squamous Cell Carcinoma: Results from a Phase II Cohort
    • May Cho, MD, University of California, Irvine, CA
  • Stereotactic Ablative Radiotherapy for Early-stage Glottic Larynx Carcinoma: Results from the Phase II LT-SABR Study
    • David Sher, University of Texas Southwestern Medical Center, Dallas
  • Standard but Not Equal: Disparities in Advanced Radiotherapy Techniques for Head and Neck Cancer in the United States
    • Neal McCall, Winship Cancer Institute of Emory University, Atlanta
  • Focal Adhesion Kinase Drives Resistance to Therapy in HPV-Negative Head and Neck Squamous Cell Carcinoma in a P53-Dependent Manner
    • Phillip Pifer, UPMC Hillman Cancer Center, Pittsburgh
12:20 p.m. – 1:20 p.m. Lunch in the Exhibit Hall
Early-career and Trainee Networking Luncheon: Launching Your Successful Career
  • How to Get Your Paper Published
    • Renata Ferrarotto, MD, MD Anderson Cancer Center, Houston, Texas [M]
  • Finding Personal/Professional Balance
    • Cherie-Ann Nathan, MD, Louisiana State University-Health, Shreveport, Louisiana [HNS]
  • Seeking Out and Maintaining Mentoring Relationships
    • Zain Husain, MD, Sunnybrook Health Sciences Centre, Ontario, Canada [Dermatologist]
1:20 p.m. – 2:35 p.m. Panel: Thyroid
Moderator: Sue Yom, MD, PhD, FASTRO, University of California, San Francisco [R]
  • Mutational Landscape of Thyroid Cancers
    • Nabil Saba, MD, FACP, Winship Cancer Institute of Emory University, Atlanta [M]
  • Low Risk Thyroid Cancer/RAI
    • Jennifer Sipos, MD, The Ohio State University, Columbus, Ohio [Endocrinologist]
  • Therapies for High Risk and Anaplastic Thyroid Cancer
    • Saad Khan, MD, Stanford University, Stanford, California [M]
  • Multimodality Therapy for Aggressive Differentiated Thyroid Cancers
    • Mark Zafereo, MD, FACS, MD Anderson Cancer Center, Houston [HNS]
2:35 p.m. – 3:00 p.m. Coffee Break
3:00 p.m. – 4:30 p.m. HOT Topic: Options in Advanced Skin Squamous Cell Carcinoma
Moderator: Robert Ferris, MD, PhD, University of Pittsburgh [R]
  • Controversies in Surgical Management
    • Cecelia Schmalbach, MD, MSc, FACS, Temple Health, Philadelphia [HNS]
  • Role of Radiation
    • ​Shlomo Koyfman, MD, Cleveland Clinic, Cleveland [R]
  • Systemic Therapy
    • Jessica Geiger, MD, Cleveland Clinic Cancer Center, Cleveland [M
  • Immunotherapy in Special Populations
    • Anne Chang, MD, Stanford University, Stanford, California [Dermatologist]
  • Questions and Answers
4:30 p.m. – 5:30 p.m. Development of Survivorship Programs
Moderator: Jon Irish, MD, MSc, FRCSC, FACS, University of Toronto, Toronto, Ontario,Canada [HNS]
  • Developing Care Pathways
    • Liza Blumenfeld, MA, CCC-SLP, BCS-S, University of California, San Diego [SLP]
  • Practice and Research
    • Marci Lee Nilsen, PhD, RN, University of Pittsburgh, Pittsburgh [RN]
  • Financial Toxicity
    • Jonas de Souza, MD, MBA, HCA Healthcare, Nashville [M]
  • Questions and Answers
Saturday, February 26, 2022

7:00 a.m. – 12:15 p.m. Registration Open
7:00 a.m. – 8:00 a.m. Continental Breakfast
7:55 a.m. – 8:00 a.m. Day Three Welcome
Faye Johnson, MD, PhD, MD Anderson Cancer Center, Houston [M]
8:00 a.m. – 8:20 a.m. Patient Perspective
David Burkett
8:20 a.m. – 9:45 a.m. De-escalation for HPV
Moderator: Katherine Hutcheson, PhD, MD Anderson Cancer Center, Houston, [SLP]
  • Introduction
    • Katherine Hutcheson, PhD, MD Anderson Cancer Center, Houston [SLP]
  • Surgical Considerations
    • Umamaheswar Duvvuri, MD, PhD, University of Pittsburgh, Pittsburgh [HNS]
  • Radiation Considerations
    • Bhisham Chera, MD, UNC School of Medicine, Chapel Hill, North Carolina [R]
  • Systemic Considerations
    • Neil Hayes, MD, The University of Tennessee Health Science Center, Memphis, Tennessee [M]
  • Questions and Answers
9:45 a.m. – 10:30 a.m. Salivary Cancers
Moderator: Assuntina Gesualda Sacco, MD, University of California, San Diego, Moores Cancer Center, La Jolla, California [M]
  • Current Approaches to Managing Salivary Cancer
    • Kiran Kakarala, MD, University of Kansas Medical Center, Kansas City, Kansas [HNS]
  • Novel Systemic Treatment for Recurrent or Metastatic Salivary Cancers
    • Renata Ferrarotto, MD, MD Anderson Cancer Center, Houston [M]
  • Questions and Answers
10:30 a.m. – 10:45 a.m. Coffee Break
10:45 a.m. – 12:15 p.m. Recurrent and Metastatic Head and Neck Cancer
Moderator: Farzan Siddiqui, MD, PhD, Henry Ford Cancer Institute, Detroit [R]
  • Re-irradiation for Recurrent and Second Primary Head and Neck Cancers
    • Neal Dunlap, MD, University of Louisville, Louisville, Kentucky [R] ​
  • Surgical Salvage with Reconstruction
    • Urjeet Patel, MD, Northwestern Hospital, Chicago [HNS]
  • Novel Targeted and Immunotherapies
    • Christine Chung, MD, Moffitt Cancer Center, Tampa, Florida [M]
  • Case Discussions

- Orders under 45$ will have a shipping charge of a flat rate of 15$.

-Orders over 45$ will have Free Shipping.

This site is protected by hCaptcha and the hCaptcha Privacy Policy and Terms of Service apply.

Testimonials

★★★★★


“I find the taste of Moringa tea to be very refreshing and it definitely gives me a feeling of ‘wellness’. I appreciate the ethics of the company. Am looking forward to trying the cream”

Elain
★★★★★


”I love knowing that everything is 100% chemical-free and tested in Canada. I also respect the sustainable farming approach that supports both Canada and Ethiopia.”

Alycia
★★★★★

Since I drink Moringa Tea I feel so much better. My mouth was always so dry but since I drink this tea I have so much saliva I drool.

I cannot believe how much it has helped me with my breathing. I love it. I even eat all the leaves - Thank you for introducing me to this herbal tea. I'm 85 years old.

Richard Dorge
Winnipeg, MB

Recently viewed